bgb-16673 + sonrotoclax

BGB-16673 + sonrotoclax is an investigational oral combination therapy being explored primarily for the treatment of hematologic malignancies, particularly B-cell malignancies such as relapsed/refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia (WM). BGB-16673 is a bivalent small molecule classified as a proteolysis targeting chimera (PROTAC) and acts as a chimeric degradation activation compound (CDAC) that selectively targets Bruton’s tyrosine kinase (BTK) for ubiquitination and proteasomal degradation, resulting in inhibition of both wildtype and mutant forms of BTK. This is designed to overcome BTK inhibitor resistance commonly observed in B-cell malignancies. Sonrotoclax is a potent, orally available BCL-2 inhibitor (not explicitly detailed in the provided search results but well-established in published literature) which promotes apoptosis in BCL-2–dependent cancer cells. In combination, the agents are intended to provide synergistic antitumor activity by dual targeting of key survival pathways in B-cell malignancies. BGB-16673 is developed by BeiGene, and the combination is under clinical investigation in multi-center studies.